Phaseline

Companies › Tvardi Therapeutics

Tvardi Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 1; Oncology; next expected readout May 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
TTI-101–Phase 1Hepatocellular Carcinoma; Pancreatic CancerMay 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05440708TTI-101Phase 1Hepatocellular CarcinomaOncologyMay 2027
NCT06141031TTI-101Phase 1Pancreatic CancerOncologyJun 2029

From the company's SEC filings

Cash of $16m on 2026-06-30; operating cash outflow about $31m a year; runway about 6 months at that burn, to Jan 2027

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.